News

The country's only double-board certified pediatric and cosmetic dermatologist shared what he learned from 5 unique patient cases this year.

James Song, MD, addressed current challenges in the AD treatment landscape and compared biologics.

Jason Hawkes, MD, MS, gives an overview of what clinicians need to know today about this rare condition.

Raj Chovatiya, MD, PhD, focused on understanding JAK inhibitors, discussing their clinical use and safety profiles for effective patient communication.

Catch up on coverage from the second day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Keep up with the latest headlines in dermatology from the past week, including US sunscreen versus global regulations, all-time high melanoma rates in the UK, and more.

Marc Serota, MD, provided clinical pearls to consider for patients on biologics, particularly dupilumab.

Raj Chovatiya, MD, PhD, takes a deep dive in the challenges, solutions, and further research needed to treat seborrheic dermatitis.

James Song, MD, discusses the current treatment landscape, genetic and immunological influences, and the role of oral minoxidil in alopecia areata.

Ben Lockshin, MD, FAAD, delves into the new generation of oral psoriasis therapies to enhance patient quality of life.

The trial results indicated 3 significant improvements across all AHFD subtypes with dupilumab treatment compared to placebo.

Catch up on coverage from the first day of the 2024 Fall Clinical Dermatology Conference for PAs and NPs in Scottsdale, Arizona.

Improvements persisted through the 12-week post-treatment follow-up, indicating sustained efficacy even after discontinuation of dupilumab.

Four leaders in HS treatment and care put a spotlight on the latest clinical trial data and treatment techniques.

Terry Arnold, PA-C, shared his journey and advice for PAs and NPs looking to transition out of a clinical practice.

Significant improvements were observed in EASI scores across all anatomical regions, regardless of patient age or specific body region.

Earlier this week, we shared our fourth and final Skin Cancer Awareness Month quiz. Review the answers and your responses below.

Dermatology Times is looking back on the top stories in dermatology from the month of May.

Dermatology Times will bring clinical insights from leading experts in numerous dermatology specialties.

Novartis announced late-breaking data for the BTK inhibitor at the 2024 European Academy of Allergy and Clinical Immunology Congress.

Raj Chovatiya, MD, PhD, reviews the varying degrees of influence of skin barrier disruption, immune dysregulation, and Malassezia yeast in seborrheic dermatitis.

The phase 2 study achieved the primary end point of a >30% Severity of Alopecia Tool score improvement.

Dermatology Times is recapping our top expert interviews from the month of May.

May is Asian American and Pacific Islander Heritage Month. We review articles from the past month spotlighting dermatologic concerns in this patient population.

Chovatiya was a lead author of the latest seborrheic dermatitis and roflumilast foam review published in the Journal of Clinical and Aesthetic Dermatology.

Learn more about the in-depth topics covered in the May 2024 supplement of Dermatology Times.

The treatment is the first IL-17 targeting topical therapy being developed for less severe cases of psoriasis.

Learn more about the in-depth topics covered in the May 2024 print issue of Dermatology Times.

The study is the first to be approved by the European Medicines Agency to perform human clinical trials with a novel therapeutic mAb.

Miranti previews her sessions from the meeting which kicks off tomorrow, May 30, in Orlando, Florida.